Fennec Pharmaceuticals v. Cipla: Sodium Thiosulfate Patent Case Consolidated in New Jersey
Fennec Pharmaceuticals filed suit against Cipla Limited in the District of New Jersey asserting US12311026B2, covering PEDMARK® sodium thiosulfate injection, against Cipla’s generic single-use vials. The case was consolidated with a related proceeding within 48 days of filing, suggesting coordinated multi-front enforcement strategy.
Fennec’s multi-docket PEDMARK® enforcement consolidated into single NJ action
On May 27, 2025, Fennec Pharmaceuticals, Inc. filed suit against Cipla Limited in the U.S. District Court for the District of New Jersey, asserting US12311026B2 — a patent covering sodium thiosulfate injection formulations marketed as PEDMARK® for the prevention of cisplatin-induced ototoxicity in pediatric patients. The accused products are Cipla’s generic single-use vials of sodium thiosulfate, consistent with an ANDA-type challenge to Fennec’s branded product.
On July 14, 2025 — just 48 days after filing — the court granted Fennec’s Motion to Consolidate Cases, merging docket 2:25-cv-05709 into a pre-existing related case. The consolidation order reflects no merits adjudication on infringement or validity; the substance of Fennec’s claims against Cipla will proceed in the consolidated proceeding. Consolidation of this nature typically signals the court’s preference for judicial efficiency when multiple cases share common patents, products, or defendants.
The rapid resolution of this docket — under 50 days — is a procedural outcome, not a substantive one, and should not be read as a win or loss for either party. The public record on this docket is silent on claim construction positions, any Cipla defenses, or settlement posture. What remains to be watched is whether the consolidated case will proceed to a Markman hearing or resolve through settlement, a path common in ANDA litigation involving pediatric oncology-support drugs.
Filing to Case Consolidated in 48 days
Case resolved by consolidation in 48 days — well below median ANDA litigation timelines
Case consolidated: what the court’s order means for both parties
Consolidation merges dockets — litigation continues elsewhere
Consolidation under Fed. R. Civ. P. 42(a) allows a court to combine cases that share common questions of law or fact. Here, the court granted Fennec’s motion, merging this docket into an existing related case. The 48-day docket is effectively absorbed — no claims are dismissed, no rights are waived, and Cipla remains a defendant. All future activity on Fennec’s PEDMARK® claims against Cipla will appear under the consolidated case number.
No merits ruling issuedFennec retains full claim posture in consolidated proceeding
Consolidation was sought and granted on Fennec’s motion, suggesting Fennec views a unified proceeding as strategically preferable — likely because it strengthens claim construction consistency and avoids conflicting rulings across dockets. Fennec’s infringement claims under US12311026B2 survive intact. The PEDMARK® patent remains fully asserted against Cipla’s generic sodium thiosulfate vials, and no adverse substantive ruling has been entered on this docket.
Claims fully preservedCipla faces consolidated litigation with potentially broader exposure
For Cipla, consolidation means facing Fennec’s patent assertions within a proceeding that may involve additional defendants or related ANDA filers. Consolidated cases can increase discovery burden and limit the ability to pursue independent claim construction strategies. Cipla’s defenses — whether validity challenges, non-infringement positions, or design-around arguments — will now be litigated alongside any co-defendants in the merged docket. No public record exists of Cipla’s substantive response on this short-lived docket.
Defense continues in merged casePEDMARK® exclusivity battle shifts to consolidated forum
PEDMARK® holds FDA approval as the first drug specifically indicated to reduce cisplatin-induced hearing loss in pediatric patients — a narrow but clinically significant market. Consolidation of multiple generic challengers into one proceeding is consistent with multi-ANDA enforcement strategy and may extend the effective exclusivity window for Fennec if the consolidated case proceeds slowly. For generic entrants across the sodium thiosulfate injection space, the litigation risk profile is now concentrated in a single New Jersey docket.
Exclusivity window in focusFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Fennec Pharmaceuticals, Inc. | Company | Pharmaceutical company — holder of US12311026B2, PEDMARK® sodium thiosulfate injectionSearch in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Cipla Limited — global generic pharmaceutical manufacturer challenging PEDMARK® exclusivitySearch in Eureka ↗ |
| Plaintiff counsel | John D. Tortorella | Attorney | Counsel for Fennec Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Kevin Harry Marino | Attorney | Counsel for Fennec Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Marino Tortorella & Boyle, PC | Law Firm | Representing Fennec Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is purely procedural — the court found that docket 2:25-cv-05709 shares sufficient commonality with the existing related case to warrant merger under Rule 42(a). No infringement finding, no validity ruling, and no claim construction positions have been established on this docket. For practitioners monitoring this dispute, the operative forum is now the consolidated proceeding, where Fennec’s substantive claims under US12311026B2 against Cipla’s generic sodium thiosulfate vials will be adjudicated.
US12311026B2 — PEDMARK® sodium thiosulfate injection for pediatric ototoxicity
US12311026B2 (application number US18/606860) covers sodium thiosulfate injection formulations associated with PEDMARK®, the first FDA-approved drug indicated specifically to reduce the risk of ototoxicity caused by cisplatin chemotherapy in pediatric patients. The patent sits within a narrow but commercially significant therapeutic niche — protecting a formulation designed to address a well-documented side effect of platinum-based chemotherapy regimens used in children. Its grant reflects IP coverage of both formulation and potentially administration-related aspects of the product.
For the generic pharmaceutical sector, US12311026B2 represents a meaningful barrier to entry in the sodium thiosulfate injectable space. PEDMARK® occupies a relatively uncontested originator position; any company pursuing an ANDA referencing this product must navigate this patent as well as any associated FDA exclusivity periods. The multi-defendant enforcement pattern visible in this consolidated litigation suggests Fennec is actively policing the boundary of its formulation IP. Competitors, contract manufacturers, and ANDA filers should treat this patent as a high-priority FTO target before advancing clinical or regulatory programs.
Should your team run an FTO against US12311026B2?
Any pharmaceutical company, contract development and manufacturing organisation (CDMO), or ANDA filer with a sodium thiosulfate injectable product in development should treat US12311026B2 as a primary FTO target. The consolidated litigation in New Jersey confirms that Fennec is actively asserting this patent against at least one major generic manufacturer. If your product references PEDMARK® or shares formulation characteristics with the patented sodium thiosulfate injection, an FTO assessment is not optional — it is prerequisite to any regulatory filing or commercial launch decision.
PatSnap Eureka’s FTO Search Agent enables IP and R&D teams to run structured freedom-to-operate analyses against US12311026B2, mapping your formulation parameters against asserted claim scope and identifying prior art or design-around opportunities. Eureka can also surface related Fennec patents and pending applications that may form a broader exclusivity stack around PEDMARK®, giving your team a complete picture of the IP landscape before committing to an ANDA or NDA filing strategy.
Run a freedom-to-operate analysis on US12311026B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent infringement cases: sodium thiosulfate & pediatric pharma IP
Explore related ANDA infringement actions involving pharmaceutical formulation patents litigated in the District of New Jersey and comparable U.S. district courts.
What this case signals for the pediatric oncology pharmaceutical IP landscape
Fennec’s consolidation motion and rapid court approval suggests an organised, multi-front enforcement posture around PEDMARK® that competitors in the sodium thiosulfate space should monitor closely.
Multi-ANDA enforcement is Fennec’s likely playbook for PEDMARK® protection
The existence of at least two related dockets — and Fennec’s successful motion to consolidate — is consistent with a coordinated strategy to assert US12311026B2 against multiple generic filers simultaneously. Companies developing or filing ANDAs referencing PEDMARK® should anticipate swift litigation responses and assess the consolidated proceeding’s scope before advancing.
Consolidation signals judicial efficiency preference — early settlement pressure possible
When courts consolidate ANDA cases this quickly, it often concentrates settlement leverage. Generic defendants in a consolidated proceeding may face shared discovery costs and a unified claim construction — factors that historically increase settlement probability before trial, particularly in paediatric drug markets with limited commercial runway for generics.
Fennec v Cipla — key questions answered
The case was closed after 48 days when the court granted Fennec’s Motion to Consolidate Cases on July 14, 2025. Docket 2:25-cv-05709 was merged into a pre-existing related proceeding in the District of New Jersey. No merits ruling on infringement or validity was issued on this docket.
Fennec asserts US12311026B2 (application US18/606860), which covers sodium thiosulfate injection formulations associated with PEDMARK® — an FDA-approved drug indicated to reduce cisplatin-induced ototoxicity in pediatric patients. Cipla’s accused products are generic single-use vials of sodium thiosulfate.
Consolidation means Cipla remains a defendant — no claims were dropped. The dispute over US12311026B2 continues in the consolidated New Jersey proceeding. Cipla may now litigate alongside other ANDA defendants, potentially sharing discovery obligations and facing a unified claim construction ruling that applies to all parties.
PEDMARK® received FDA approval as the first drug specifically indicated to reduce cisplatin-induced hearing loss in pediatric patients, which may attract orphan drug or pediatric exclusivity protections in addition to patent coverage under US12311026B2. The public docket is silent on the specific exclusivity periods claimed; companies assessing FTO should evaluate the full regulatory exclusivity stack independently.
Consolidation within 48 days of filing is consistent with a patent holder that filed multiple related ANDA suits and sought to streamline proceedings. Courts grant consolidation under Rule 42(a) when cases share common facts or legal questions. The speed here suggests both judicial efficiency preference and Fennec’s proactive enforcement coordination, which typically concentrates settlement pressure and claim construction risk for all generic defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.